» Articles » PMID: 36233625

Prevention of Surgery-Induced Dry Eye by Diquafosol Eyedrops After Femtosecond Laser-Assisted Cataract Surgery

Overview
Journal J Clin Med
Specialty General Medicine
Date 2022 Oct 14
PMID 36233625
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To analyze the protective effects of diquafosol eyedrops on the ocular surface following femtosecond laser-assisted cataract surgery (FLACS). Design: A prospective, randomized contralateral study. Methods: Bilateral FLACS with a trifocal IOL (PanOptix) implantation was performed in 40 eyes in 20 patients (10 males, 10 females, average age 68.8 ± 6.3 years old). Patients received 3% diquafosol eyedrops six times daily in one randomly chosen eye (diquafosol group), and physiological saline six times a day in the other eye (control group). Other medication included 1.5% levofloxacin, 0.1% dexamethasone and 0.1% diclofenac three times daily in both eyes. The pre and post-operative tear break-up time (BUT), superficial punctate keratopathy (SPK) scores and visual function were compared between both eyes, and all patients answered the dry-eye-related quality of life score (DEQS) questionnaire. Results: The BUT between groups was similar pre-operatively and on the first day post-op; however, the BUT was statistically longer in the diquafosol group compared to saline at 1 week (5.5/3.7 s) and 2 weeks (4.8/3.0 s) (p < 0.05). There was no difference in the SPK score, best corrected distance visual acuity, tear meniscus height, contrast sensitivity, DEQS and Schirmer test at all time points. Spherical aberration was statistically lower in the diquafosol group at 1 week. The protective effects of diquafosol on the BUT was more pronounced in patients with a pre-operative BUT of less than 5 s compared with those with a BUT longer than 6 s. Conclusions: Diquafosol eyedrops prevented the shortening of the BUT following FLACS, even in patients with short pre-operative BUT values.

Citing Articles

Short-term application of diquafosol ophthalmic solution benefits children with dry eye wearing orthokeratology lens.

Yang Y, Wu Q, Tang Y, Wu H, Luo Z, Gao W Front Med (Lausanne). 2023; 10:1130117.

PMID: 37521335 PMC: 10374404. DOI: 10.3389/fmed.2023.1130117.

References
1.
Miyake K, Yokoi N . Influence on ocular surface after cataract surgery and effect of topical diquafosol on postoperative dry eye: a multicenter prospective randomized study. Clin Ophthalmol. 2017; 11:529-540. PMC: 5364011. DOI: 10.2147/OPTH.S129178. View

2.
Fujihara T, Murakami T, Fujita H, Nakamura M, Nakata K . Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. Invest Ophthalmol Vis Sci. 2001; 42(1):96-100. View

3.
Kojima T, Dogru M, Ibrahim O, Nagata T, Higa K, Shimizu T . The effects of 3% diquafosol sodium application on the tear functions and ocular surface of the Cu,Zn-superoxide dismutase-1 (Sod1)-knockout mice. Mol Vis. 2014; 20:929-38. PMC: 4077595. View

4.
Pendergast W, Yerxa B, Douglass 3rd J, Shaver S, DOUGHERTY R, Redick C . Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates. Bioorg Med Chem Lett. 2001; 11(2):157-60. DOI: 10.1016/s0960-894x(00)00612-0. View

5.
Jumblatt J, Jumblatt M . Regulation of ocular mucin secretion by P2Y2 nucleotide receptors in rabbit and human conjunctiva. Exp Eye Res. 1998; 67(3):341-6. DOI: 10.1006/exer.1998.0520. View